Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19863380 | 1.00 | TDP1 (0.34) | TDP1 | |
| SCHEMBL19863379 | 1.00 | TDP1 (0.34) | TDP1 | |
| SCHEMBL19867125 | 0.85 | — | — | |
| SCHEMBL1944719 | 0.81 | EPHX2 (0.32) | — | |
| SCHEMBL21474582 | 0.77 | EPHX2 (0.34) | — | |
| SCHEMBL23317514 | 0.75 | TDP1 (0.35) | TDP1 | |
| SCHEMBL23999395 | 0.74 | — | — | |
| SCHEMBL25111818 | 0.74 | — | — | |
| SCHEMBL12113242 | 0.74 | — | — | |
| SCHEMBL21191167 | 0.73 | EPHX2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10973828-B2 | Biaryl compositions and methods for modulating a kinase cascade | ATHENEX, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20190125754-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | OAKTREE FUND ADMINISTRATION, LLC | 2019-05-02 | — | — | US | disclosed |
| US-20180042934-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | OAKTREE FUND ADMINISTRATION, LLC | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180042934-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | PLK1, MAP3K2, TNK2 | TDP1 1442/4885 |
| US-20190125754-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | PLK1, MAP3K2, TNK2 | TDP1 1442/4885 |
| US-10973828-B2 | Biaryl compositions and methods for modulating a kinase cascade | PLK1, MAP3K2, TNK2 | TDP1 1442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.